| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion due to NICE appraisal TA129: Bortezomib monotherapy for relapsed multiple myeloma |
|
Medicine details |
|
| Medicine name | bortezomib (Velcade®) |
| Formulation | powder for solution for injection |
| Reference number | 64 |
| Indication | Treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplantation |
| Company | Janssen-Cilag Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 23/11/2005 |
| NICE guidance | |